| Identification | Back Directory | [Name]
2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol | [CAS]
1898283-02-7 | [Synonyms]
CS-2805
LY-3200882
2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol
2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol
4-[[4-[[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol
2-Pyridinemethanol, 4-[[4-[[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl- | [Molecular Formula]
C24H29N5O3 | [MDL Number]
MFCD31619238 | [MOL File]
1898283-02-7.mol | [Molecular Weight]
435.52 |
| Chemical Properties | Back Directory | [Boiling point ]
607.2±55.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:108.5(Max Conc. mg/mL);249.12(Max Conc. mM) | [form ]
A crystalline solid | [pka]
13.45±0.29(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
4-[[4-[[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol is used to prepare aminopyridyloxypyrazole compounds as TGFβR1 inhibitors. | [in vivo]
LY3200882 (60 mg/kg; oral gavage; twice a day; for 21 days; BALB/C female mice) treatment significantly delays tumor growth in CT26 model[2].
LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion[1].
LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer)[1]. | Animal Model: | BALB/C female mice (5-8-week-old) injected with CT26 cells[2] | | Dosage: | 60 mg/kg | | Administration: | Oral gavage; twice a day; for 21 days | | Result: | A statistically significant tumor growth delay in CT26 model was observed.
|
|
|
|